



ASX ANNOUNCEMENT

25 September 2024

CHIMERIC & ACHIEVE CLINICS FORM COLLABORATION TO EXPAND THE REACH OF CHM'S CELL THERAPIES

- Chimeric Therapeutics is developing CHM CDH17, the world's first cadherin 17-directed CAR-T cell therapy, and is recruiting GI cancer patients to a clinical trial in the United States (NCT06055439)
- Achieve Clinics is revolutionising the cancer patient's journey to future cell therapies through PRO-Aph™, a zero-cost option for patients to undergo proactive apheresis
- Chimeric and Achieve will collaborate to enable the use of product collected from apheresis, which is cryopreserved from patients according to Achieve Clinics process, for the manufacture of CHM CDH17

Sydney, Australia, 25 September 2024: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce a partnership with Achieve Clinics ("Achieve"), a Los Angeles, California biotechnology company dedicated to improving patient access to autologous cell therapies.

Achieve's PRO-Aph™ transforms how patients access cell therapies because they do not have to wait until the standard of care fails them before beginning to contemplate a possible future cell therapy option. Waiting for cancer to progress while experiencing systemic chemotherapy complicates the logistics of the leukopheresis and renders the collected cells less likely to deliver an effective CAR T. PRO-Aph™ mitigates these issues by proactively collecting patients' cells while they are still at their healthiest point.

"The use of patients' cells that have previously been exposed to chemotherapy and the logistical challenges of just-in-time manufacturing have a negative impact both on patients trying to access these new medicines and cell therapy companies working to advance their clinical programs," said Jason B Litten MD, Chief Medical Officer of Chimeric. "We believe Achieve's revolutionary approach will streamline our future development plans and make it easier for patients to access CHM CDH17."

"Achieve is excited to support Chimeric's clinical trial, especially given that it is one of the only CAR Ts with IND clearance in advanced gastrointestinal cancers," said Brad Heller, PhD, Chief Executive Officer of Achieve Clinics. "Advanced GI cancer patients are prone to bleeding issues that make apheresis risky, so being able to support this patient population early in their cancer treatment is especially meaningful. We are excited to help more patients gain easier access to CHM CDH17, while improving accrual rates and development timelines."



Under the collaboration, Achieve Clinics will perform PRO-Aph™ proactive collection and storage of autologous cell therapy starting material from appropriately consented patients with gastrointestinal cancer or other applicable diagnoses. Collected patients will become part of Achieve's PRO-Aph™ participant registry from which Chimeric may screen and enrol patients once eligible. Collected cells will then be used to manufacture CHM CDH17 for eligible patients. Any unused patient cells can be used for future research purposes.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes various cell therapies across multiple disease areas in oncology with 3 clinical stage programs. CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. Based on that compelling preclinical dataset, CHM CDH17 has entered the clinic in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that is enrolling subjects at cancer centres in the United States.

ABOUT ACHIEVE CLINICS

Achieve Clinics is a privately held company based in Los Angeles, California that connects cancer patients to autologous cell therapies they may need in the future. These medicines are made from a patient's own cells, which make them difficult to manufacture and even harder for patients to access. Achieve is dedicated to helping any patient who can benefit from a cell therapy treatment to receive it.

PRO-Aph, a free-to-patient proactive leukopheresis, cell processing and cryopreservation service is the central component of the Achieve Clinics solution. PRO-Aph allows Achieve to build a registry of patients proactively for autologous cell therapies being developed by Achieve's partners. These patients can be proactively enrolled and their apheresis product may be



procured on-demand to accelerate accrual and streamline the supply chain. The entire cell therapy ecosystem can benefit from the unused portions of PRO-Aph not sequestered for future clinical use because these unique biospecimens can be used for discovery science and process development in order to bring more products to market more quickly.

Achieve Clinics is proud to partner with Blood Centers of America to provide leukopheresis and cell processing operational infrastructure through members of its Advanced Therapies Network, including Vitalant. Together, we are rolling out the Achieve Clinics Process so that one day, any patient who can benefit from a future cell therapy will be able to undergo the PRO-Aph procedure and achieve their best chance for a cure.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Dr Rebecca McQualter
Chief Operating Officer
Chimeric Therapeutics
T: + 61 498 966 180
E: RMcQualter@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au